LINE-1 elements are the only autonomously active retrotransposons in the human genome, and although the vast majority of copies are silenced by epigenetic mechanisms, they can be reawakened in cancer. When that happens, LINE-1 open reading frame proteins, particularly ORF1p, are produced at high levels, and retrotransposition activity generates new insertions, DNA double-strand breaks, and cytoplasmic DNA fragments. These products are recognized by the cell as signs of danger. In many tumor types, LINE-1 overexpression has been linked to a phenomenon sometimes described as viral mimicry, in which the cell behaves as though it were infected by a pathogen, switching on innate immune signaling pathways that include interferon responses and inflammatory gene programs.

Homologous recombination deficiency, or HRD, is another hallmark of genomic chaos. Cells with HRD cannot accurately repair double-strand breaks through the template-based homologous recombination pathway, forcing them to rely on error-prone alternatives such as non-homologous end joining. The result is an accumulating burden of mutations, structural rearrangements, and scars in the genome, including characteristic patterns of loss of heterozygosity and telomeric allelic imbalance that can be scored as an HRD signature. HRD is well established as a predictive biomarker in ovarian, breast, pancreatic, and prostate cancers, where it predicts sensitivity to platinum chemotherapy and PARP inhibitors, but its role in gastric cancer—particularly in combination with retrotransposon activity—has been far less explored.

The new research set out to determine whether gastric cancers with high LINE-1 expression and HRD represent a distinct biological subgroup with heightened immune activation. Drawing on genomic and transcriptomic data from gastric cancer cohorts, the investigators stratified tumors according to LINE-1 retrotransposon overexpression and the presence of homologous recombination deficiency signatures, then compared immune pathway activity, immune cell infiltration, and clinically relevant molecular features across the resulting groups. The analysis integrated somatic mutation patterns, copy number alterations, mutational signatures, and expression of immune checkpoint molecules to build a comprehensive picture of the tumor microenvironment in each subgroup.

The central finding is striking: gastric tumors that combine LINE-1 overexpression with HRD show significantly stronger activation of immune signaling pathways than tumors lacking either feature. Interferon-gamma and interferon-alpha response programs, antigen processing and presentation machinery, and cytotoxic T lymphocyte activity are all enriched in this double-positive subgroup. The tumors also display greater infiltration by CD8-positive T cells and other immune effector populations, along with elevated expression of immune checkpoint genes including PD-L1, the molecular target of a class of immunotherapy drugs already used in advanced gastric cancer. In contrast, tumors without LINE-1 activation or HRD tend to show comparatively cold immune profiles with less inflammatory signaling.

From a mechanistic standpoint, the convergence of these two sources of genomic instability makes biological sense. Retrotransposon reactivation floods the cytoplasm and nucleus with aberrant nucleic acids that engage DNA sensors such as cGAS and activate the STING pathway, a central conduit to type I interferon production. At the same time, defective homologous recombination allows DNA damage to persist and diversify, generating neoantigens from accumulated mutations and further amplifying danger signaling. Together, these processes can convert an otherwise self-contained genomic meltdown into a visible inflammatory signal that recruits and activates immune cells. The study’s data suggest that in gastric cancer, LINE-1 activity and HRD are not merely parallel markers of instability but may act synergistically to shape an inflamed, immune-responsive tumor microenvironment.

The clinical implications are considerable. Immune checkpoint inhibitors have transformed the treatment of several cancers, but in gastric cancer only a subset of patients derives durable benefit, and better biomarkers are urgently needed to identify responders. If the combination of LINE-1 overexpression and HRD reliably marks a hyperinflamed, checkpoint-sensitive tumor state, it could complement existing predictors such as microsatellite instability, Epstein-Barr virus status, PD-L1 expression scores, and tumor mutational burden. Notably, the LINE-1–HRD subgroup described in the study is molecularly distinct from microsatellite instability–high tumors, meaning it could flag immunotherapy candidates among patients who would otherwise be missed by standard testing.

The findings also open therapeutic avenues beyond checkpoint blockade. Tumors with homologous recombination deficiency are classically vulnerable to PARP inhibitors and platinum-based chemotherapy, agents that exploit the repair defect to push cancer cells past the point of viable DNA damage. Combining such DNA-damage-targeted strategies with immunotherapy is an area of intense investigation, on the rationale that DNA-damaging treatment can further increase neoantigen release and immune priming. Meanwhile, pharmacological reactivation of silenced retrotransposons—for example through epigenetic drugs such as DNA methyltransferase or histone deacetylase inhibitors—is being explored as a way to induce viral mimicry in tumors that lack endogenous immune activation. The new study raises the possibility that in gastric cancer, patients whose tumors already harbor LINE-1 activity and HRD may be primed for exactly these combination approaches, whereas patients with silent genomes might need epigenetic priming first.

The research also underscores how much of cancer biology is written by the repetitive, transposable elements that make up nearly half of the human genome. Long dismissed as junk DNA, these sequences are increasingly recognized as sensors and amplifiers of cellular stress. In colorectal, esophageal, and other gastrointestinal cancers, LINE-1 expression has been associated with aggressive disease and, in some contexts, with immune evasion through interferon-mediated upregulation of checkpoint ligands. The gastric cancer findings add nuance to this picture by showing that retrotransposon activation can coincide with, rather than simply undermine, productive antitumor immunity—particularly when it occurs against the backdrop of a broken DNA repair system.

Important questions remain before these observations can be translated into routine clinical practice. The study’s conclusions rest on retrospective analysis of existing cohorts, and prospective validation in independent patient populations will be essential to confirm that the LINE-1–HRD immune signature predicts immunotherapy response. Standardized assays for measuring LINE-1 expression, such as ORF1p immunohistochemistry or targeted RNA sequencing, and validated algorithms for scoring HRD in gastric cancer will need to be developed and harmonized across laboratories. It will also be important to determine whether the immune activation seen in this subgroup translates into longer survival or better response rates in patients treated with checkpoint inhibitors, and whether resistance mechanisms emerge through immune editing or further retrotransposon-driven evolution. Longitudinal studies tracking LINE-1 activity and HRD scores during treatment could reveal whether these features are stable biomarkers or dynamic players in the evolutionary arms race between tumor and immune system.

Even at this early stage, the study offers a compelling reframing of genomic instability in gastric cancer. Rather than viewing retrotransposon activation and DNA repair deficiency solely as engines of tumor progression, the work positions them as potential Achilles’ heels—sources of the very molecular noise that the immune system can detect and attack. As biomarker panels for gastric cancer grow more sophisticated, the ancient jumping genes embedded in our chromosomes may earn a place alongside viral status and repair signatures as guides to treatment decisions. For patients facing an aggressive and often treatment-resistant disease, that shift could mean the difference between a tumor that hides from the immune system and one that announces itself loudly enough to be destroyed.

Subject of Research: Immune pathway activation in gastric cancers with LINE-1 retrotransposon overexpression and homologous recombination deficiency

Article Title: Immune pathway activation in gastric cancers with LINE-1 retrotransposon overexpression and homologous recombination deficiency

Article References: Kim, Y. J., Baek, I.-P., Eom, B. W., Seo, M.-J., Joo, H., Choi, Y. R., Park, M. K., Oh, J., Lee, B., Ham, S. M., Choi, N.-H., Hong, S.-P., Choi, J., Kim, S., Kong, S.-H., Lee, H.-J., Suh, Y.-S., Kong, J., Rhee, J.-K., … Yang, H. K. (2026). Immune pathway activation in gastric cancers with LINE-1 retrotransposon overexpression and homologous recombination deficiency. Experimental & Molecular Medicine. https://doi.org/10.1038/s12276-026-01846-5

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01846-5

Keywords: gastric cancer, LINE-1 retrotransposon, homologous recombination deficiency, immune pathway activation, immunotherapy, biomarkers, genomic instability, PD-L1, interferon signaling, tumor microenvironment, PARP inhibitors, viral mimicry